ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Cansino Biologics Inc (PK)

Cansino Biologics Inc (PK) (CASBF)

2,60
0,00
(0,00%)
Geschlossen 12 Juli 10:00PM

Cansino Biologics Inc (PK) (CASBF) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
2,60
( - )
Gebot
2,53
Fragen
3,42
Volumen
-
Durchschnittliches Volumen (3 Mio.)
US$ 1.031.481
Finanzvolumen
-
0,00 Tagesbereich 0,00
2,60 52-Wochen-Bereich 6,99
Marktkapitalisierung
Unternehmenswert
7,191B
Handelsende
2,60
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
VWAP
-
Erlöse (LTM)
1,12B
Nettogewinn (LTM)
-1,01M
Ausgegebene Aktien
247.043.801
Streubesitz (%)
64,72%
Institutioneller Besitz (%)
8,13%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-5,15k
Kurs-Umsatz-Verhältnis (KUV)
7,53
Gewinn pro Aktie (EPS)
-0
Beta
1,2

Über Cansino Biologics Inc (PK)

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningit... CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China. Mehr anzeigen

Sektor
-
Branche
-
Website
Hauptsitz
Tianjin, China
Gegründet
2026
Cansino Biologics Inc (PK) is listed in the sector of the OTC Markets with ticker CASBF. The last closing price for Cansino Biologics (PK) was US$2,60. Over the last year, Cansino Biologics (PK) shares have traded in a share price range of US$ 2,60 to US$ 6,99.

Cansino Biologics (PK) currently has 247.043.801 shares in issue. The market capitalisation of Cansino Biologics (PK) is US$642,31 million. Cansino Biologics (PK) has a price to earnings ratio (PE ratio) of -5,153.58.

CASBF Neueste Nachrichten

Keine Nachrichten vorhanden.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1002.62.62.62002.6CS
4-0.26-9.090909090912.862.862.61332.665CS
12-1.26-32.64248704663.8642.64363.48577982CS
26-2.145-45.20547945214.7454.7452.63713.66320498CS
52-2.4-4856.992.614944.38147055CS
156-0.9-25.71428571433.56.991.8618343.38157845CS
260-38.19-93.625888698240.7949.021.86232015.30330979CS

CASBF - Frequently Asked Questions (FAQ)

What is the current Cansino Biologics Inc (PK) share price?
The current share price of Cansino Biologics Inc (PK) is US$ 2,60
How many Cansino Biologics Inc (PK) shares are in issue?
Cansino Biologics Inc (PK) has 247.043.801 shares in issue
What is the market cap of Cansino Biologics Inc (PK)?
The market capitalisation of Cansino Biologics Inc (PK) is USD 642,31M
What is the 1 year trading range for Cansino Biologics Inc (PK) share price?
Cansino Biologics Inc (PK) has traded in the range of US$ 2,60 to US$ 6,99 during the past year
What is the PE ratio of Cansino Biologics Inc (PK)?
The price to earnings ratio of Cansino Biologics Inc (PK) is -5,15k
What is the cash to sales ratio of Cansino Biologics Inc (PK)?
The cash to sales ratio of Cansino Biologics Inc (PK) is 7,53
What is the registered address of Cansino Biologics Inc (PK)?
The registered address for Cansino Biologics Inc (PK) is 401-420, Biomedical Park, Tianjin, 300457
What is the Cansino Biologics Inc (PK) website address?
The website address for Cansino Biologics Inc (PK) is cansinotech.com

CASBF Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen